All In Biotech

NDA 016455 · Almirall

Cordran

Flurandrenolide · Topical · Corticosteroid

Last checked: Nov 19, 2026Latest source record: Jan 13, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1969

Jul 29, 1969

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2

1 Phase 3, 0 recruiting

FAERS reports

333

152 serious, 6 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 29, 1969 Original approval · Type 3 - New Dosage Form
1 products under this application
  • CORDRAN · FLURANDRENOLIDE 0.004MG/SQ CM · TAPE, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Flurandrenolide" as an intervention, any sponsor and status, largest first.

All 2 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pruritus31
  • drug ineffective30
  • headache20
  • nausea20
  • rash19
  • fatigue18
  • pain18
  • diarrhoea16
  • psoriasis16
  • depression14
  • dyspnoea14
  • pain in extremity14

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20051
20064
20072
20091
20104
20116
20124
20139
201411
201524
201620
201731
201822
201931
202024
202118
202222
202327
202420
202522
202627

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cordran (Flurandrenolide)

2024 spending

$3.4M

Beneficiaries

1,781

3,293 claims

Per beneficiary

$1,910

$796.61 per unit

View as table
YearSpending
2020$3,082,695
2021$3,887,544
2022$3,549,294
2023$3,438,698
2024$3,401,214

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3 on PubMed

Sponsor: Almirall

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.